Monte Rosa Therapeutics vs Stoke Therapeutics
Stoke Therapeutics is the larger business, with $184m of revenue in fiscal 2025 against $124m for Monte Rosa Therapeutics (1.5 times as much). Stoke Therapeutics grew faster (404.5% against 63.5%). Stoke Therapeutics kept more of each dollar of sales as profit: a net margin of -3.7% against -31.2%. Monte Rosa Therapeutics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Monte Rosa TherapeuticsGLUE, 2025 | Stoke TherapeuticsSTOK, 2025 |
|---|---|---|
| Revenue | $124m | $184m |
| Revenue growth | 63.5% | 404.5% |
| Net income | −$38.6m | −$6.9m |
| Operating margin | -43.8% | -11.2% |
| Net margin | -31.2% | -3.7% |
| Return on equity | -16.9% | -2.4% |
| Free cash flow | −$27.5m | $44.9m |
| Cash | $130m | $84.2m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | 0.0% | — |
| Share buybacks | — | — |
| Employees | 150 | 170 |
| Market value | $894m | $1.69bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 37 sales | 0 buys, 83 sales |